For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
|
| Basic information |
| Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
| HSIEH DAR JEN |
HSIEH DAR JEN |
TONY TSENG |
07-6955569 |
2nd Fl., No. 57, Luke 2nd Rd., Lujhu Dist.Kaohsiung City 82151, Taiwan R.O.C. |
2021/07/27 |
| Industrycategory |
Key businesses |
| Biotechnology and Medical Care |
ACRO Biomedical focuses on research and development of biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). Tissue engineering and regenerative medicine combines three key elements: cell, signal, and scaffold. With the interaction of these three element, the defects or damages of tissues and organs can be repaired and reconstructed. The biomaterials prepared by ACRO’s proprietary supercritical CO2 technology serve a great purpose as scaffolds in one of three key elements, which provide the intact collagen scaffolds that will not cause immune reaction. A:Fully developed products that are decellularized and processed from porcine issues B:Products in development--1. Collagen Implant2. Cartilage Graft3. Collagen Ophthalmic Matrix, Cornea Graft C:Products applied in cell therapy—1.Skin Regeneration. 2.Cartilage Regeneration D:Organ regeneration in development--Customized organs: heart, liver, and kidney |
| Financial data |
| Cash flows statement
| Item
|
|
|
| Amount(NTD, in thousands) |
| Cash flows from operating activities |
|
|
| Cash flows from investing activities |
|
|
| Cash flows from financing activities |
|
|
Consolidated/Individual
balance sheet
|
Current assets |
|
|
| Non-current assets |
|
|
| Total assets |
|
|
| Current liabilities |
|
|
| Non-current liabilities |
|
|
| Total liabilities |
|
|
| Share capital |
|
|
| Capital surplus |
|
|
| Retained earnings |
|
|
| Other equity interest |
|
|
| Treasury shares |
|
|
| Total equity attributable to owners of parent |
|
|
| Non-controlling interests |
|
|
| Total equity |
|
|
| Book Value per share(NT$) |
|
|
Consolidated/Individual
profit and loss
statement |
Operating revenue |
|
|
| Operating costs |
|
|
| Gross profit from operations |
|
|
| Operating expenses |
|
|
| Net other income (expenses) |
|
|
| Net operating income |
|
|
| Non-operating income and expenses |
|
|
| Profit before tax |
|
|
| Tax expense |
|
|
| Profit from continuing operations |
|
|
| Profit from discontinued operations |
|
|
| Profit |
|
|
| Other comprehensive income |
|
|
| Comprehensive income |
|
|
| Basic earnings per share |
|
|
 Auditor's report on latest financial statements： auditor's report：
|
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|
